Pyriform cortex

WHO Recommendations for Diabetes and Intermediate Hyperglycaemia Diagnosis

The World Health Organization (WHO) has established diagnostic criteria for diabetes and intermediate hyperglycaemia. According to the 2006 recommendations, a fasting plasma glucose level of 7.0 mmol/L (126 mg/dL) or higher, or a 2-hour plasma glucose level of 11.1 mmol/L (200 mg/dL) or higher indicates diabetes. On the other hand, impaired glucose tolerance (IGT) is diagnosed when the fasting plasma glucose level is less than 7.0 mmol/L (126 mg/dL) and the 2-hour plasma glucose level is between 7.8 and 11.1 mmol/L (140 mg/dL and 200 mg/dL). Impaired fasting glucose (IFG) is diagnosed when the fasting plasma glucose level is between 6.1 and 6.9 mmol/L (110 mg/dL to 125 mg/dL) and the 2-hour plasma glucose level is less than 7.8 mmol/L (140 mg/dL), if measured.

It is important to note that if the 2-hour plasma glucose level is not measured, the status of the individual is uncertain as diabetes or IGT cannot be excluded. These recommendations serve as a guide for healthcare professionals in diagnosing and managing diabetes and intermediate hyperglycaemia.

The appropriate course of action for a patient with poorly controlled hypertension who is already taking an ACE inhibitor is to add indapamide to their medication regimen. This is in accordance with the NICE treatment algorithm, which recommends adding a calcium channel blocker or a thiazide-like diuretic in such cases. It is important to note that nifedipine should be avoided in patients with heart failure, and that amlodipine is the only calcium channel blocker licensed for use in such patients. Continuing to monitor blood pressure at home and reviewing in one month would not be sufficient in this case, as the patient’s hypertension needs to be addressed more aggressively. Stopping ramipril and trying amlodipine instead is not recommended, as combination therapy is the preferred approach. Similarly, stopping ramipril and trying amlodipine with indapamide instead is not recommended, as the combination should not be used in place of an ACE inhibitor.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

The M rule for primary biliary cholangitis includes the presence of IgM and anti-Mitochondrial antibodies, specifically the M2 subtype, in middle-aged women.

Primary Biliary Cholangitis: A Chronic Liver Disorder

Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a chronic liver disorder that is commonly observed in middle-aged women. The exact cause of this condition is not yet fully understood, but it is believed to be an autoimmune disease. The disease is characterized by the progressive damage of interlobular bile ducts due to chronic inflammation, leading to cholestasis and eventually cirrhosis. The most common symptom of primary biliary cholangitis is itching in middle-aged women.

This condition is often associated with other autoimmune diseases such as Sjogren’s syndrome, rheumatoid arthritis, systemic sclerosis, and thyroid disease. Early symptoms of primary biliary cholangitis may be asymptomatic or may include fatigue, pruritus, and cholestatic jaundice. Late symptoms may progress to liver failure. Diagnosis of primary biliary cholangitis involves immunology tests such as anti-mitochondrial antibodies (AMA) M2 subtype and smooth muscle antibodies, as well as imaging tests to exclude an extrahepatic biliary obstruction.

The first-line treatment for primary biliary cholangitis is ursodeoxycholic acid, which slows down the progression of the disease and improves symptoms. Cholestyramine is used to alleviate pruritus, and fat-soluble vitamin supplementation is recommended. In severe cases, liver transplantation may be necessary, especially if bilirubin levels exceed 100. However, recurrence in the graft can occur, but it is not usually a problem. Complications of primary biliary cholangitis include cirrhosis, portal hypertension, ascites, variceal hemorrhage, osteomalacia, osteoporosis, and an increased risk of hepatocellular carcinoma.

The most common organism associated with bronchiectasis is Haemophilus influenzae, making it the correct answer for an acute exacerbation of this condition. While Klebsiella pneumonia is also a possibility, it is less frequently seen and typically associated with pneumonia in patients with alcohol dependence. Pseudomonas aeruginosa is an incorrect answer, as it is more commonly found in patients with cystic fibrosis than bronchiectasis. Staphylococcus aureus is also less commonly isolated in bronchiectasis, and is more commonly associated with other infective conditions such as infective endocarditis and skin infections, as well as being a secondary bacterial cause of pneumonia following influenzae.

Managing Bronchiectasis

Bronchiectasis is a condition where the airways become permanently dilated due to chronic inflammation or infection. Before starting treatment, it is important to identify any underlying causes that can be treated, such as immune deficiency. The management of bronchiectasis includes physical training, such as inspiratory muscle training, which has been shown to be effective for patients without cystic fibrosis. Postural drainage, antibiotics for exacerbations, and long-term rotating antibiotics for severe cases are also recommended. Bronchodilators may be used in selected cases, and immunizations are important to prevent infections. Surgery may be considered for localized disease. The most common organisms isolated from patients with bronchiectasis include Haemophilus influenzae, Pseudomonas aeruginosa, Klebsiella spp., and Streptococcus pneumoniae.

Spacing:

Bronchiectasis is a condition where the airways become permanently dilated due to chronic inflammation or infection. Before starting treatment, it is important to identify any underlying causes that can be treated, such as immune deficiency.

The management of bronchiectasis includes physical training, such as inspiratory muscle training, which has been shown to be effective for patients without cystic fibrosis. Postural drainage, antibiotics for exacerbations, and long-term rotating antibiotics for severe cases are also recommended. Bronchodilators may be used in selected cases, and immunizations are important to prevent infections. Surgery may be considered for localized disease.

The most common organisms isolated from patients with bronchiectasis include Haemophilus influenzae, Pseudomonas aeruginosa, Klebsiella spp., and Streptococcus pneumoniae.

Widespread convulsions without loss of consciousness may indicate a psychogenic non-epileptic seizure (pseudoseizure), especially in a patient with psychiatric comorbidities. A focal aware seizure would not involve whole-body convulsions, while an alcohol withdrawal seizure would involve loss of consciousness. A panic attack may involve involuntary movement, but widespread convulsions would be unusual.

Understanding Psychogenic Non-Epileptic Seizures

Psychogenic non-epileptic seizures, also known as pseudoseizures, are a type of seizure that is not caused by abnormal electrical activity in the brain. Instead, they are believed to be caused by psychological factors such as stress, trauma, or anxiety. These seizures can be difficult to diagnose as they often mimic true epileptic seizures, but there are certain factors that can help differentiate between the two.

Factors that may indicate pseudoseizures include pelvic thrusting, a family history of epilepsy, a higher incidence in females, crying after the seizure, and the seizures not occurring when the individual is alone. On the other hand, factors that may indicate true epileptic seizures include tongue biting and a raised serum prolactin level.

Video telemetry is a useful tool for differentiating between the two types of seizures. It involves monitoring the individual’s brain activity and behavior during a seizure, which can help determine whether it is caused by abnormal electrical activity in the brain or psychological factors.

It is important to accurately diagnose and treat psychogenic non-epileptic seizures as they can have a significant impact on an individual’s quality of life. Treatment may involve therapy to address underlying psychological factors, as well as medication to manage any associated symptoms such as anxiety or depression.

The patient’s symptoms and elevated troponin levels suggest a diagnosis of myocardial infarction. The ECG findings indicate a posterior myocardial infarction, as evidenced by tall R waves and ST depression in leads V1 and V2. This is because the infarct is located in the posterior region, causing a reversal of the lead findings. It is important to note that not all patients with myocardial infarction will present with classic symptoms. Anterior ST elevation myocardial infarction and inferior myocardial infarction are both incorrect diagnoses. A posterior myocardial infarction with tall R waves is a type of ST-elevation myocardial infarction (STEMI) and requires different management than a non-ST-elevation myocardial infarction (NSTEMI).

The following table displays the relationship between ECG changes and the corresponding coronary artery territories. Anteroseptal changes in V1-V4 indicate involvement of the left anterior descending artery. Inferior changes in II, III, and aVF suggest the right coronary artery is affected. Anterolateral changes in V1-6, I, and aVL indicate the proximal left anterior descending artery is involved. Lateral changes in I, aVL, and possibly V5-6 suggest the left circumflex artery is affected. Posterior changes in V1-3 may indicate a posterior infarction, which is confirmed by ST elevation and Q waves in posterior leads (V7-9). This type of infarction is usually caused by the left circumflex artery, but can also be caused by the right coronary artery. Reciprocal changes of STEMI are typically seen as horizontal ST depression, tall and broad R waves, upright T waves, and a dominant R wave in V2. It is important to note that a new left bundle branch block (LBBB) may indicate acute coronary syndrome.

Overall, understanding the correlation between ECG changes and coronary artery territories is crucial in diagnosing acute coronary syndrome. By identifying the specific changes in the ECG, medical professionals can determine which artery is affected and provide appropriate treatment. Additionally, recognizing the reciprocal changes of STEMI and the significance of a new LBBB can aid in making an accurate diagnosis.

Distinguishing between Acute Kidney Injury and Chronic Kidney Disease

One of the most effective ways to differentiate between acute kidney injury (AKI) and chronic kidney disease (CKD) is through the use of renal ultrasound. In most cases, patients with CKD will have small kidneys that are bilateral. However, there are some exceptions to this rule, including individuals with autosomal dominant polycystic kidney disease, diabetic nephropathy in its early stages, amyloidosis, and HIV-associated nephropathy.

In addition to renal ultrasound, there are other features that can suggest CKD rather than AKI. For example, individuals with CKD may experience hypocalcaemia due to a lack of vitamin D. By identifying these distinguishing factors, healthcare professionals can more accurately diagnose and treat patients with kidney disease. Proper diagnosis is crucial, as the treatment and management of AKI and CKD differ significantly.

Understanding Primary Hyperaldosteronism

Primary hyperaldosteronism is a medical condition that was previously believed to be caused by an adrenal adenoma, also known as Conn’s syndrome. However, recent studies have shown that bilateral idiopathic adrenal hyperplasia is the cause in up to 70% of cases. It is important to differentiate between the two as this determines the appropriate treatment. Adrenal carcinoma is an extremely rare cause of primary hyperaldosteronism.

The common features of primary hyperaldosteronism include hypertension, hypokalaemia, and alkalosis. Hypokalaemia can cause muscle weakness, but this is seen in only 10-40% of patients. To diagnose primary hyperaldosteronism, the 2016 Endocrine Society recommends a plasma aldosterone/renin ratio as the first-line investigation. This should show high aldosterone levels alongside low renin levels due to negative feedback from sodium retention caused by aldosterone.

If the plasma aldosterone/renin ratio is high, a high-resolution CT abdomen and adrenal vein sampling are used to differentiate between unilateral and bilateral sources of aldosterone excess. If the CT is normal, adrenal venous sampling (AVS) can be used to distinguish between unilateral adenoma and bilateral hyperplasia. The management of primary hyperaldosteronism depends on the underlying cause. Adrenal adenoma is treated with surgery, while bilateral adrenocortical hyperplasia is treated with an aldosterone antagonist such as spironolactone.

In summary, primary hyperaldosteronism is a medical condition that can be caused by adrenal adenoma, bilateral idiopathic adrenal hyperplasia, or adrenal carcinoma. It is characterized by hypertension, hypokalaemia, and alkalosis. Diagnosis involves a plasma aldosterone/renin ratio, high-resolution CT abdomen, and adrenal vein sampling. Treatment depends on the underlying cause and may involve surgery or medication.

Neutropenic sepsis is a serious condition that requires immediate treatment with antibiotics. Piperacillin with tazobactam (Tazocin) is the preferred antibiotic for this condition, even before neutropenia is confirmed on blood testing. This combination works by breaking down the cell walls of bacteria and preventing bacterial resistance to piperacillin. However, if a patient is unable to tolerate Tazocin, alternative antibiotics should be considered based on local guidelines or microbiology advice.

Amoxicillin with clavulanic acid and gentamicin are other antibiotics that can be used for severe infections, but they are not the best choice for neutropenic sepsis. Aztreonam and vancomycin can be used in combination when Tazocin is not an option, but a third antibiotic may be necessary for additional coverage. It is important to note that gentamicin should be used with caution due to the risk of kidney damage and ototoxicity.

Neutropenic Sepsis: A Common Complication of Cancer Therapy

Neutropenic sepsis is a frequent complication of cancer therapy, particularly chemotherapy. It typically occurs within 7-14 days after chemotherapy and is characterized by a neutrophil count of less than 0.5 * 109 in patients undergoing anticancer treatment who exhibit a temperature higher than 38ºC or other signs or symptoms consistent with clinically significant sepsis.

To prevent neutropenic sepsis, patients who are likely to have a neutrophil count of less than 0.5 * 109 as a result of their treatment should be offered a fluoroquinolone. In the event of neutropenic sepsis, antibiotics must be initiated immediately, without waiting for the white blood cell count.

According to NICE guidelines, empirical antibiotic therapy should begin with piperacillin with tazobactam (Tazocin) immediately. While some units may add vancomycin if the patient has central venous access, NICE does not support this approach. After initial treatment, patients are typically assessed by a specialist and risk-stratified to determine if they may be able to receive outpatient treatment.

If patients remain febrile and unwell after 48 hours, an alternative antibiotic such as meropenem may be prescribed, with or without vancomycin. If patients do not respond after 4-6 days, the Christie guidelines suggest ordering investigations for fungal infections (e.g. HRCT) rather than blindly initiating antifungal therapy. In selected patients, G-CSF may be beneficial.

The first-line treatment for syphilis is intramuscular benzathine penicillin, which is the correct management for the most likely diagnosis based on the patient’s symptoms of rash, lymphadenopathy, buccal ulcers, and condylomata, indicating secondary syphilis. The presence of a palmar rash is highly indicative of syphilis, although HIV should also be tested for as it can coexist with syphilis and present with similar symptoms. Cryotherapy is a treatment option for genital warts, but the flat white appearance of the wart-like lesions described here suggests they are more likely to be condylomata lata. The suggestion of no specific treatment except hydration and rest is incorrect, as this would only be appropriate for self-limiting viral illnesses such as Epstein-Barr virus, which is a potential differential diagnosis but less likely given the characteristic rash and history of the patient.

Management of Syphilis

Syphilis can be effectively managed with intramuscular benzathine penicillin as the first-line treatment. In cases where penicillin cannot be used, doxycycline may be used as an alternative. After treatment, nontreponemal titres such as rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) should be monitored to assess the response. A fourfold decline in titres is often considered an adequate response to treatment.

It is important to note that the Jarisch-Herxheimer reaction may occur following treatment. This reaction is characterized by fever, rash, and tachycardia after the first dose of antibiotic. Unlike anaphylaxis, there is no wheezing or hypotension. The reaction is thought to be due to the release of endotoxins following bacterial death and typically occurs within a few hours of treatment. However, no treatment is needed other than antipyretics if required.

In summary, the management of syphilis involves the use of intramuscular benzathine penicillin or doxycycline as an alternative. Nontreponemal titres should be monitored after treatment, and the Jarisch-Herxheimer reaction may occur but does not require treatment unless symptomatic.

An adrenaline infusion can be used as an alternative treatment for symptomatic bradycardia if transcutaneous pacing is not available. In this case, the patient requires rapid intervention to address their haemodynamic instability. Atropine infusion is not appropriate due to the patient’s allergy and potential to worsen their condition. Amiodarone is not useful in this situation, as it is typically used for other arrhythmias. Digoxin is not helpful in bradycardia and can actually reduce AV conduction speed. Glucagon is reserved for cases of cardiovascular failure caused by beta-blocker overdose, which is not the case for this patient.

Management of Bradycardia in Peri-Arrest Rhythms

The 2021 Resuscitation Council (UK) guidelines highlight that the management of bradycardia in peri-arrest rhythms depends on two factors. Firstly, identifying adverse signs that indicate haemodynamic compromise, such as shock, syncope, myocardial ischaemia, or heart failure. Secondly, identifying the potential risk of asystole, which can occur in patients with complete heart block with broad complex QRS, recent asystole, Mobitz type II AV block, or ventricular pause > 3 seconds.

If adverse signs are present, Atropine (500 mcg IV) is the first line treatment. If there is an unsatisfactory response, interventions such as atropine (up to a maximum of 3mg), transcutaneous pacing, or isoprenaline/adrenaline infusion titrated to response may be used. Specialist help should be sought for consideration of transvenous pacing if there is no response to the above measures.

Even if there is a satisfactory response to atropine, specialist help is indicated to consider the need for transvenous pacing in patients with risk factors for asystole. By following these guidelines, healthcare professionals can effectively manage bradycardia in peri-arrest rhythms and improve patient outcomes.

Hyperventilation leads to a respiratory alkalosis (non-compensated) due to the reduction in carbon dioxide levels.

Disorders of Acid-Base Balance: An Overview

The acid-base normogram is a useful tool for categorizing the various disorders of acid-base balance. Metabolic acidosis is the most common surgical acid-base disorder, characterized by a reduction in plasma bicarbonate levels. This can be caused by a gain of strong acid (such as in diabetic ketoacidosis) or a loss of base (such as from bowel in diarrhea). Metabolic alkalosis, on the other hand, is usually caused by a rise in plasma bicarbonate levels, which can be due to problems of the kidney or gastrointestinal tract. Respiratory acidosis occurs when there is a rise in carbon dioxide levels, usually as a result of alveolar hypoventilation, while respiratory alkalosis results from hyperventilation, leading to excess loss of carbon dioxide.

Each of these disorders has its own set of causes and mechanisms. For example, metabolic alkalosis can be caused by vomiting/aspiration, diuretics, or primary hyperaldosteronism, among other factors. The mechanism of metabolic alkalosis involves the activation of the renin-angiotensin II-aldosterone (RAA) system, which causes reabsorption of Na+ in exchange for H+ in the distal convoluted tubule. Respiratory acidosis, on the other hand, can be caused by COPD, decompensation in other respiratory conditions, or sedative drugs like benzodiazepines and opiate overdose.

It is important to understand the different types of acid-base disorders and their causes in order to properly diagnose and treat them. By using the acid-base normogram and understanding the underlying mechanisms, healthcare professionals can provide effective interventions to restore balance to the body’s acid-base system.

Conditions Associated with DVT and Factors Not Contributing to Increased Risk

Deep vein thrombosis (DVT) can be linked to various medical conditions, including polycythaemia, underlying carcinoma (indicated by high prostate specific antigen [PSA]), lympho- or myeloproliferative diseases, and thrombophilias such as antithrombin 3 deficiency or lupus anticoagulant. However, in cases where the patient has low sodium levels, it suggests overhydration rather than dehydration, and high prothrombin time does not increase the risk of thrombosis. Diabetes, indicated by a glucose level of 7.2 mmol/L, does not contribute to an increased risk of DVT. It is important to consider these factors when assessing a patient’s risk of DVT.

Genetics and Types of Colorectal Cancer

Colorectal cancer is a type of cancer that affects the colon and rectum. There are three main types of colorectal cancer: sporadic, hereditary non-polyposis colorectal carcinoma (HNPCC), and familial adenomatous polyposis (FAP). Sporadic colon cancer is the most common type, accounting for 95% of cases. It is believed to be caused by a series of genetic mutations, including allelic loss of the APC gene, activation of the K-ras oncogene, and deletion of p53 and DCC tumour suppressor genes.

HNPCC, also known as Lynch syndrome, is an autosomal dominant condition that accounts for 5% of cases. It is the most common form of inherited colon cancer and is caused by mutations in genes involved in DNA mismatch repair, leading to microsatellite instability. The most commonly affected genes are MSH2 and MLH1. Patients with HNPCC are also at a higher risk of developing other cancers, such as endometrial cancer.

FAP is a rare autosomal dominant condition that accounts for less than 1% of cases. It is caused by a mutation in the adenomatous polyposis coli gene (APC), which leads to the formation of hundreds of polyps by the age of 30-40 years. Patients with FAP inevitably develop carcinoma and are also at risk of duodenal tumors. A variant of FAP called Gardner’s syndrome can also feature osteomas of the skull and mandible, retinal pigmentation, thyroid carcinoma, and epidermoid cysts on the skin.

In conclusion, understanding the genetics behind colorectal cancer is important for diagnosis and treatment. While sporadic colon cancer is the most common type, HNPCC and FAP are inherited conditions that require genetic testing and surveillance for early detection and prevention.

If initial treatment for dyspepsia with either a PPI or ‘test and treat’ approach fails, the other approach should be tried next. NICE guidelines recommend prescribing a full-dose PPI for 1 month or testing for H. pylori infection and prescribing eradication therapy if positive. If symptoms persist, switch to the alternative strategy. Referral for routine upper GI endoscopy is not indicated at this stage.

Management of Dyspepsia and Referral for Possible Cancer

Dyspepsia is a common symptom that can be caused by various factors, including medication and lifestyle choices. However, it can also be a sign of underlying conditions such as stomach or oesophageal cancer. The 2015 NICE guidelines provide updated advice on when urgent referral for endoscopy is necessary. Patients with dysphagia or an upper abdominal mass consistent with stomach cancer should be referred urgently. Patients aged 55 years or older with weight loss and upper abdominal pain, reflux, or dyspepsia should also be referred urgently. Non-urgent referrals include patients with haematemesis or those with treatment-resistant dyspepsia, upper abdominal pain with low haemoglobin levels, or raised platelet count with other symptoms.

For patients with undiagnosed dyspepsia, a step-wise approach is recommended. First, medications should be reviewed for possible causes. Lifestyle advice should also be given. If symptoms persist, a trial of full-dose proton pump inhibitor for one month or a ‘test and treat’ approach for H. pylori can be tried. If symptoms persist after either approach, the alternative should be attempted. Testing for H. pylori infection can be done using a carbon-13 urea breath test, stool antigen test, or laboratory-based serology. If symptoms resolve following test and treat, there is no need to check for H. pylori eradication. However, if repeat testing is required, a carbon-13 urea breath test should be used.

If the level of LDH in an effusion is greater than 2/3rds of the upper limit of LDH in the serum, it indicates an exudate according to Light’s criteria.

Investigating and Managing Pleural Effusion: BTS Guidelines

Pleural effusion is a condition where fluid accumulates in the pleural space, the area between the lungs and the chest wall. To investigate and manage this condition, the British Thoracic Society (BTS) has provided guidelines.

Imaging is an essential part of the investigation process, and the BTS recommends performing posterioranterior (PA) chest x-rays in all patients. Ultrasound is also recommended as it increases the likelihood of successful pleural aspiration and is sensitive for detecting pleural fluid septations. Contrast CT is increasingly performed to investigate the underlying cause, particularly for exudative effusions.

Pleural aspiration is another crucial step in the investigation process. The BTS recommends using ultrasound to reduce the complication rate. A 21G needle and 50ml syringe should be used, and fluid should be sent for pH, protein, lactate dehydrogenase (LDH), cytology, and microbiology. Light’s criteria can help distinguish between a transudate and an exudate. Other characteristic pleural fluid findings include low glucose in rheumatoid arthritis and tuberculosis, raised amylase in pancreatitis and oesophageal perforation, and heavy blood staining in mesothelioma, pulmonary embolism, and tuberculosis.

In cases of pleural infection, diagnostic pleural fluid sampling is required for all patients with a pleural effusion in association with sepsis or a pneumonic illness. If the fluid is purulent or turbid/cloudy, a chest tube should be placed to allow drainage. If the fluid is clear but the pH is less than 7.2 in patients with suspected pleural infection, a chest tube should be placed.

For managing recurrent pleural effusion, options include recurrent aspiration, pleurodesis, indwelling pleural catheter, and drug management to alleviate symptoms such as opioids to relieve dyspnoea. The BTS guidelines provide a comprehensive approach to investigating and managing pleural effusion.

ROSIER is an acronym for a tool used to assess stroke symptoms in an acute setting.

Assessment and Investigations for Stroke

Whilst diagnosing a stroke may be straightforward in some cases, it can be challenging when symptoms are vague. The FAST screening tool, which stands for Face/Arms/Speech/Time, is a well-known tool used by the general public to identify stroke symptoms. However, medical professionals use a validated tool called the ROSIER score, recommended by the Royal College of Physicians. The ROSIER score assesses for loss of consciousness or syncope, seizure activity, and new, acute onset of asymmetric facial, arm, or leg weakness, speech disturbance, or visual field defect. A score of greater than zero indicates a likely stroke.

When investigating suspected stroke, a non-contrast CT head scan is the first line radiological investigation. The key question to answer is whether the stroke is ischaemic or haemorrhagic, as this determines the appropriate management. Ischaemic strokes may show areas of low density in the grey and white matter of the territory, while haemorrhagic strokes typically show areas of hyperdense material surrounded by low density. It is important to identify the type of stroke promptly, as thrombolysis and thrombectomy play an increasing role in acute stroke management. In rare cases, a third pathology such as a tumour may also be detected.

For patients under 65 years old with subclinical hypothyroidism and a TSH level between 5.5-10mU/L, a 6-month trial of thyroxine should be offered if they have hypothyroidism symptoms and their TSH remains elevated on two separate occasions 3 months apart. This is because subclinical hypothyroidism increases the risk of cardiovascular disease and progression to overt hypothyroidism, and treatment with levothyroxine generally resolves symptoms. Repeat thyroid autoantibody tests and thyroid function testing after 3 months are unnecessary if the patient has already had negative autoantibody results and two elevated TSH levels 3 months apart. Prescribing levothyroxine only if further symptoms develop is not recommended as it delays treatment and increases the risk of negative impacts on the patient’s quality of life.

Understanding Subclinical Hypothyroidism

Subclinical hypothyroidism is a condition where the thyroid-stimulating hormone (TSH) is elevated, but the levels of T3 and T4 are normal, and there are no obvious symptoms. However, there is a risk of the condition progressing to overt hypothyroidism, especially in men, with a 2-5% chance per year. This risk is further increased if thyroid autoantibodies are present.

Not all patients with subclinical hypothyroidism require treatment, and guidelines have been produced by NICE Clinical Knowledge Summaries (CKS) to help determine when treatment is necessary. If the TSH level is above 10mU/L and the free thyroxine level is within the normal range, levothyroxine may be offered. If the TSH level is between 5.5 – 10mU/L and the free thyroxine level is within the normal range, a 6-month trial of levothyroxine may be considered if the patient is under 65 years old and experiencing symptoms of hypothyroidism. For older patients, a ‘watch and wait’ strategy is often used, and asymptomatic patients may simply have their thyroid function monitored every 6 months.

In summary, subclinical hypothyroidism is a condition that requires careful monitoring and consideration of treatment options based on individual patient factors.

The likely diagnosis for this patient is hypercalcaemia, as indicated by their symptoms of polyuria, polydipsia, constipation, abdominal pain, depression, weakness, and fatigue. The main ECG abnormality associated with hypercalcaemia is a shortened QT interval. It is important to note that the presence of a J-wave is typically seen in hypothermia, not hypercalcaemia. Additionally, a prolonged QT interval is a feature of hypocalcaemia, not hypercalcaemia. Finally, tall tented T waves are characteristic of hyperkalaemia, not hypercalcaemia.

Hypercalcaemia: Symptoms and Signs

Hypercalcaemia is a medical condition characterized by high levels of calcium in the blood. The symptoms and signs of hypercalcaemia can be remembered by the phrase ‘bones, stones, groans and psychic moans’. This means that patients with hypercalcaemia may experience bone pain, kidney stones, constipation, and changes in mood or behavior. In addition, corneal calcification and a shortened QT interval on an electrocardiogram (ECG) may also be present. Hypertension, or high blood pressure, is another common feature of hypercalcaemia. It is important to seek medical attention if any of these symptoms are present, as hypercalcaemia can lead to serious complications if left untreated.

Aspirin is the recommended medication for patients with polycythaemia vera to lower the risk of thrombotic events caused by hyperviscosity. This patient is experiencing symptoms of hyperviscosity due to an excess of red blood cells in their serum. Aspirin works by inhibiting cyclooxygenase (COX) and reducing the production of thromboxane from arachidonic acid, which decreases platelet aggregation and lowers the risk of thrombotic events.

Apixaban is not the first-line prophylaxis for polycythaemia vera and is therefore incorrect for this patient. It is typically used for provoked or unprovoked deep vein thrombosis by directly inhibiting activated factor X (Xa) and preventing the conversion of prothrombin to thrombin.

Clopidogrel is an anti-platelet drug commonly used in acute coronary syndrome management but is not recognized as a treatment for polycythaemia vera in national guidelines, making it an incorrect option for this patient.

Hydroxyurea is a chemotherapy drug that is a recognized treatment for polycythaemia vera. However, it is not appropriate as a first-line option for thrombotic event prophylaxis, and aspirin should be the initial medication prescribed for this patient.

Polycythaemia vera is a condition where a single marrow stem cell undergoes clonal proliferation, leading to an increase in red cell volume, as well as an overproduction of neutrophils and platelets. This disorder is most commonly seen in individuals in their sixth decade of life and is characterized by symptoms such as hyperviscosity, pruritus, and splenomegaly.

The management of polycythaemia vera involves several approaches. Aspirin is often prescribed to reduce the risk of thrombotic events. Venesection is the first-line treatment to keep the haemoglobin levels within the normal range. Chemotherapy, such as hydroxyurea, may also be used, but it carries a slight increased risk of secondary leukaemia. Phosphorus-32 therapy is another option.

The prognosis for polycythaemia vera is variable. Thrombotic events are a significant cause of morbidity and mortality. Additionally, 5-15% of patients may progress to myelofibrosis, while another 5-15% may develop acute leukaemia, with the risk being increased with chemotherapy treatment.

In cases of acute kidney injury (AKI), it is important to identify drugs that may worsen renal function and those that can result in toxicity. AKI is defined as a 50% or greater rise in serum creatinine within the past 7 days or a fall in urine output to less than 0.5 ml/kg/hour for more than 6 hours.

For patients on aspirin for secondary prevention of acute coronary syndrome, the cardioprotective dose of 75 mg per day should be continued as there is strong evidence supporting its use. Aspirin is a COX-inhibitor that inhibits thromboxane synthesis via the COX-1 pathway, exhibiting antithrombotic effects.

Drugs that should be stopped in AKI as they may worsen renal function include diuretics, aminoglycosides, ACE inhibitors/ARBs, and NSAIDs that are not at cardioprotective doses. On the other hand, drugs that do not worsen renal function but can result in toxicity include metformin, lithium, and digoxin. A helpful mnemonic to remember the drugs to stop in AKI is DAMN AKI: Diuretics, Aminoglycosides and ACE inhibitors, Metformin, and NSAIDs.

Understanding Acute Kidney Injury: A Basic Overview

Acute kidney injury (AKI) is a condition where the kidneys experience a reduction in function due to an insult. In the past, the kidneys were often neglected in acute medicine, resulting in slow recognition and limited action. However, around 15% of patients admitted to the hospital develop AKI. While most patients recover their renal function, some may have long-term impaired kidney function due to AKI, which can result in acute complications, including death. Identifying patients at increased risk of AKI is crucial in reducing its incidence. Risk factors for AKI include chronic kidney disease, other organ failure/chronic disease, a history of AKI, and the use of drugs with nephrotoxic potential.

AKI has three main causes: prerenal, intrinsic, and postrenal. Prerenal causes are due to a lack of blood flow to the kidneys, while intrinsic causes relate to intrinsic damage to the kidneys themselves. Postrenal causes occur when there is an obstruction to the urine coming from the kidneys. Symptoms of AKI include reduced urine output, fluid overload, arrhythmias, and features of uraemia. Diagnosis of AKI is made through blood tests, urinalysis, and imaging.

The management of AKI is largely supportive, with careful fluid balance and medication review being crucial. Loop diuretics and low-dose dopamine are not recommended, but hyperkalaemia needs prompt treatment to avoid life-threatening arrhythmias. Renal replacement therapy may be necessary in severe cases. Prompt review by a urologist is required for patients with suspected AKI secondary to urinary obstruction, while specialist input from a nephrologist is necessary for cases where the cause is unknown or the AKI is severe.

For a patient with a large artery acute ischaemic stroke, mechanical clot retrieval should be considered along with intravenous thrombolysis. According to recent NICE guidance, thrombectomy should be offered as soon as possible and within 6 hours of symptom onset, along with intravenous thrombolysis (if within 4.5 hours), for patients with an acute ischaemic stroke and confirmed occlusion of the proximal anterior circulation demonstrated by computed tomographic angiography (CTA) or magnetic resonance angiography (MRA). As such, this patient should be offered both thrombolysis and clot retrieval. Anticoagulation with Apixaban is not recommended for atrial fibrillation until two weeks after the onset of an ischaemic stroke. Aspirin 300mg would be a reasonable treatment if the patient presented outside the thrombolysis window and mechanical thrombectomy was not an option. However, in this scenario, the patient is within the thrombolysis window and should be offered both thrombolysis and mechanical thrombectomy due to the timing and location of their stroke.

The Royal College of Physicians (RCP) and NICE have published guidelines on the diagnosis and management of patients following a stroke. The management of acute stroke includes maintaining normal levels of blood glucose, hydration, oxygen saturation, and temperature. Blood pressure should not be lowered in the acute phase unless there are complications. Aspirin should be given as soon as possible if a haemorrhagic stroke has been excluded. Anticoagulants should not be started until brain imaging has excluded haemorrhage. Thrombolysis with alteplase should only be given if administered within 4.5 hours of onset of stroke symptoms and haemorrhage has been definitively excluded. Mechanical thrombectomy is a new treatment option for patients with an acute ischaemic stroke. NICE recommends thrombectomy for people who have acute ischaemic stroke and confirmed occlusion of the proximal anterior circulation demonstrated by computed tomographic angiography or magnetic resonance angiography. Secondary prevention includes the use of clopidogrel and dipyridamole. Carotid artery endarterectomy should only be considered if carotid stenosis is greater than 70% according to ECST criteria or greater than 50% according to NASCET criteria.

Haemochromatosis is identified by an iron study profile that shows elevated levels of transferrin saturation and ferritin, along with a low total iron-binding capacity. This condition is inherited and leads to an excessive buildup of iron in the body. To rule out other possibilities, any options that do not show increased levels of ferritin and transferrin saturation can be eliminated during initial screening. Transferrin is a protein that transports iron in the blood, and its levels rise during iron deficiency to maximize the use of available iron. Total iron-binding capacity reflects the number of iron-binding sites on transferrin, and its levels increase during iron deficiency and decrease during iron overload.

Understanding Haemochromatosis: Investigation and Management

Haemochromatosis is a genetic disorder that causes iron accumulation in the body due to mutations in the HFE gene on both copies of chromosome 6. The best investigation to screen for haemochromatosis is still a topic of debate. For the general population, transferrin saturation is considered the most useful marker, while genetic testing for HFE mutation is recommended for testing family members. Diagnostic tests include molecular genetic testing for the C282Y and H63D mutations and liver biopsy with Perl’s stain. A typical iron study profile in a patient with haemochromatosis includes high transferrin saturation, raised ferritin and iron, and low TIBC.

The first-line treatment for haemochromatosis is venesection, which involves removing blood from the body to reduce iron levels. Transferrin saturation should be kept below 50%, and the serum ferritin concentration should be below 50 ug/l to monitor the adequacy of venesection. If venesection is not effective, desferrioxamine may be used as a second-line treatment. Joint x-rays may show chondrocalcinosis, which is a characteristic feature of haemochromatosis. It is important to note that there are rare cases of families with classic features of genetic haemochromatosis but no mutation in the HFE gene.

Sarcoidosis is the probable diagnosis based on the presence of erythema nodosum, a non-productive cough, arthralgia, and bilateral hilar lymphadenopathy on chest x-ray. This condition is known to cause hypercalcaemia due to the macrophages inside the granulomas, which increase the conversion of vitamin D to its active form. However, sarcoidosis is not typically associated with hyperkalaemia, hyponatraemia, megaloblastic anaemia, or thrombocytopenia.

Investigating Sarcoidosis

Sarcoidosis is a disease that does not have a single diagnostic test, and therefore, diagnosis is mainly based on clinical observations. Although ACE levels may be used to monitor disease activity, they are not reliable in diagnosing sarcoidosis due to their low sensitivity and specificity. Routine blood tests may show hypercalcemia and a raised ESR. A chest x-ray is a common investigation that may reveal different stages of sarcoidosis, ranging from normal (stage 0) to diffuse fibrosis (stage 4). Other investigations, such as spirometry and tissue biopsy, may also be used to diagnose sarcoidosis. However, the Kveim test, which involves injecting part of the spleen from a patient with known sarcoidosis under the skin, is no longer performed due to concerns about cross-infection.

CT scans may also be used to investigate sarcoidosis, as they can reveal nodularity and patchy areas of consolidation, particularly in the upper lobes of the lungs. It is important to note that sarcoidosis predominantly affects the upper zones of the lungs, unlike other pulmonary fibrosis conditions that affect the lower zones. Overall, a combination of clinical observations and investigations is necessary to diagnose sarcoidosis accurately.

Possible Diagnosis for a Man with Chronic Alcohol Abuse

This man, who has a history of chronic alcohol abuse, is exhibiting symptoms of a fever and left-sided hemiparesis. The most probable diagnosis for this individual would be cerebral abscess. It is unlikely that a subdural hematoma or a simple cerebrovascular accident (CVA) would explain the fever, nor would they be associated with hemiparesis. Delirium tremens or encephalopathy would not be linked to the hemiparesis either. Therefore, cerebral abscess is the most likely diagnosis for this man with chronic alcohol abuse who is experiencing a fever and left-sided hemiparesis.

The risk of oesophageal adenocarcinoma is higher in individuals with Barrett’s oesophagus, whereas those with achalasia are at a greater risk of developing squamous cell carcinoma of the oesophagus.

Oesophageal Cancer: Types, Risk Factors, Features, Diagnosis, and Treatment

Oesophageal cancer used to be mostly squamous cell carcinoma, but adenocarcinoma is now becoming more common, especially in patients with a history of gastro-oesophageal reflux disease (GORD) or Barrett’s. Adenocarcinoma is usually located near the gastroesophageal junction, while squamous cell tumours are found in the upper two-thirds of the oesophagus.

Risk factors for adenocarcinoma include GORD, Barrett’s oesophagus, smoking, achalasia, and obesity. Squamous cell cancer is more common in the developing world and is associated with smoking, alcohol, achalasia, Plummer-Vinson syndrome, and diets rich in nitrosamines.

The most common presenting symptom for both types of oesophageal cancer is dysphagia, followed by anorexia and weight loss. Other possible features include odynophagia, hoarseness, melaena, vomiting, and cough.

Diagnosis is done through upper GI endoscopy with biopsy, endoscopic ultrasound for locoregional staging, CT scanning for initial staging, and FDG-PET CT for detecting occult metastases. Laparoscopy may also be performed to detect occult peritoneal disease.

Operable disease is best managed by surgical resection, with the most common procedure being an Ivor-Lewis type oesophagectomy. However, the biggest surgical challenge is anastomotic leak, which can result in mediastinitis. Adjuvant chemotherapy may also be used in many patients.

Overall, oesophageal cancer is a serious condition that requires prompt diagnosis and treatment. Understanding the types, risk factors, features, diagnosis, and treatment options can help patients and healthcare providers make informed decisions about managing this disease.

The management of vitamin B12 deficiency typically involves intramuscular replacement of B12, with a loading regimen followed by injections every 2-3 months. Patients with this deficiency may experience symptoms such as fatigue, poor concentration, and pallor, and blood tests may confirm the presence of anemia, low B12, low folate, and hypersegmented polymorphs on a blood film. In some cases, patients may also experience thrombocytopenia due to the role of B12 as a co-factor in bone marrow cell synthesis. While patients with neurological symptoms or who are pregnant should be urgently referred, this patient does not meet those criteria. Referral to haematology may be necessary if the patient has a suspected blood disorder or malignancy, fails to respond to treatment, or has a persistently high mean cell volume. Referral to gastroenterology may be necessary if the patient has a malabsorption syndrome, gastric cancer, or pernicious anemia with gastrointestinal symptoms. Intramuscular replacement of B12 is preferred over oral replacement, as per NICE guidelines, and should always be administered prior to folate replacement to avoid spinal cord degeneration.

Understanding Pernicious Anaemia

Pernicious anaemia is a condition that results in vitamin B12 deficiency due to an autoimmune disorder affecting the gastric mucosa. The term pernicious means causing harm in a gradual or subtle way, and this is reflected in the often subtle symptoms and delayed diagnosis of the condition. While pernicious anaemia is the most common cause of vitamin B12 deficiency, other causes include atrophic gastritis, gastrectomy, and malnutrition.

The pathophysiology of pernicious anaemia involves antibodies to intrinsic factor and/or gastric parietal cells. These antibodies can bind to intrinsic factor, blocking the vitamin B12 binding site, or reduce acid production and cause atrophic gastritis. This leads to reduced intrinsic factor production and reduced vitamin B12 absorption, which can result in megaloblastic anaemia and neuropathy.

Risk factors for pernicious anaemia include being female, middle to old age, and having other autoimmune disorders such as thyroid disease, type 1 diabetes mellitus, Addison’s, rheumatoid arthritis, and vitiligo. It is also more common in individuals with blood group A.

Symptoms of pernicious anaemia include anaemia features such as lethargy, pallor, and dyspnoea, as well as neurological features such as peripheral neuropathy and subacute combined degeneration of the spinal cord. Neuropsychiatric features such as memory loss, poor concentration, confusion, depression, and irritability may also be present, along with mild jaundice and glossitis.

Diagnosis of pernicious anaemia involves a full blood count, vitamin B12 and folate levels, and testing for antibodies such as anti intrinsic factor antibodies and anti gastric parietal cell antibodies. Treatment involves vitamin B12 replacement, usually given intramuscularly, and folic acid supplementation may also be required. Complications of pernicious anaemia include an increased risk of gastric cancer.

Donepezil is classified as an acetylcholinesterase inhibitor and is considered a first-line treatment option for managing mild to moderate Alzheimer’s dementia, along with galantamine and rivastigmine. Memantine, on the other hand, is an NMDA receptor antagonist and is typically used as a second-line or adjunctive treatment for mild to moderate Alzheimer’s dementia, although it may be used as a first-line option for severe cases. Oxybutynin and tolterodine are anti-muscarinic medications that are commonly prescribed for urge incontinence, but immediate release oxybutynin should be avoided in frail older women, according to NICE guidelines. Finally, rotigotine is a dopamine agonist that is used to treat Parkinson’s disease and restless legs syndrome.

Managing Alzheimer’s Disease: Non-Pharmacological and Pharmacological Approaches

Alzheimer’s disease is a type of dementia that progressively affects the brain and is the most common form of dementia in the UK. To manage this condition, there are both non-pharmacological and pharmacological approaches available.

Non-pharmacological management involves offering a range of activities that promote wellbeing and are tailored to the patient’s preferences. Group cognitive stimulation therapy is recommended for patients with mild to moderate dementia, while group reminiscence therapy and cognitive rehabilitation are also options to consider.

Pharmacological management involves the use of medications. The three acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are options for managing mild to moderate Alzheimer’s disease. Memantine, an NMDA receptor antagonist, is considered a second-line treatment and is recommended for patients with moderate Alzheimer’s who are intolerant of or have a contraindication to acetylcholinesterase inhibitors. It can also be used as an add-on drug to acetylcholinesterase inhibitors for patients with moderate or severe Alzheimer’s or as monotherapy in severe Alzheimer’s.

When managing non-cognitive symptoms, NICE does not recommend antidepressants for mild to moderate depression in patients with dementia. Antipsychotics should only be used for patients at risk of harming themselves or others or when the agitation, hallucinations, or delusions are causing them severe distress.

It is important to note that donepezil is relatively contraindicated in patients with bradycardia, and adverse effects may include insomnia. By utilizing both non-pharmacological and pharmacological approaches, patients with Alzheimer’s disease can receive comprehensive care and management.

In the case of this patient, it is probable that she is experiencing an acute relapse of her multiple sclerosis. A urine dip has been conducted to rule out a urinary tract infection, which could also cause a flare in her symptoms (known as Uhthoff’s phenomenon). As her symptoms are new and have persisted for more than 24 hours, it is likely that she requires treatment with methylprednisolone (either intravenous or oral) to manage the relapse.

While Fingolimod, Natalizumab, and Beta-interferon are all disease modifying drugs that may reduce the frequency of relapses, they are not appropriate for treating acute relapses and should only be started in secondary care with proper drug counseling.

Amantadine may be useful in managing fatigue, but it is recommended by NICE to only be trialed for fatigue once other potential causes have been ruled out. It is unlikely to be effective in treating the patient’s other symptoms.

Multiple sclerosis is a condition that cannot be cured, but its treatment aims to reduce the frequency and duration of relapses. In the case of an acute relapse, high-dose steroids may be administered for five days to shorten its length. However, it is important to note that steroids do not affect the degree of recovery. Disease-modifying drugs are used to reduce the risk of relapse in patients with MS. These drugs are typically indicated for patients with relapsing-remitting disease or secondary progressive disease who have had two relapses in the past two years and are able to walk a certain distance unaided. Natalizumab, ocrelizumab, fingolimod, beta-interferon, and glatiramer acetate are some of the drugs used to reduce the risk of relapse in MS.

Fatigue is a common problem in MS patients, and amantadine is recommended by NICE after excluding other potential causes such as anaemia, thyroid problems, or depression. Mindfulness training and CBT are other options for managing fatigue. Spasticity is another issue that can be addressed with first-line drugs such as baclofen and gabapentin, as well as physiotherapy. Cannabis and botox are currently being evaluated for their effectiveness in managing spasticity. Bladder dysfunction is also a common problem in MS patients, and anticholinergics may worsen symptoms in some patients. Ultrasound is recommended to assess bladder emptying, and intermittent self-catheterisation may be necessary if there is significant residual volume. Gabapentin is the first-line treatment for oscillopsia, which is a condition where visual fields appear to oscillate.